Mengyuan Lei1, Chenghan Luo2, Jiayang Zhang3, Wenjun Cao4, Jian Ge4, Min Zhao5. 1. Physical Examination Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. 2. Orthopedics Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. chenghanluo@zzu.edu.cn. 3. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. 4. Neonatal Intensive Care Unit, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. 5. Medical record department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Abstract
BACKGROUND: As the most abundant modification in mRNA, the N6-methyladenosine (m6A) RNA modification is involved in the occurrence and development of various tumors. However, the underlying functions of this alteration in the immune microenvironment of lung adenocarcinoma (LUAD) remain unknown. METHODS: We identified m6A-mediated immune genes by performing a correlation analysis. Next, a m6A-mediated immune model was constructed using multiple machine learning algorithms, including univariate, least absolute shrinkage and selection operator, and multivariate Cox regression analyses. The potential of this model to predict the immune landscapes, drug sensitivities, and immunotherapy responses of different LUAD risk groups was studied. RESULTS: A m6A-mediated immune model containing 13 m6A-mediated immune genes was established and found to be an independent predictor of survival time. The prognosis of low-risk patients was significantly better than that of high-risk patients. These two risk groups displayed different immune environments, genomic backgrounds, chemotherapy responses and immunotherapy response tendencies. The low- and high-risk groups strongly corresponded to the immune-hot and immune-cold phenotypes, respectively. The low-risk group was more enriched in immune-related biological processes, and the high-risk group was more enriched in proliferation-related biological processes. Furthermore, low-risk patients responded better to immunotherapy based on the results obtained from the tumor immune dysfunction and exclusion (TIDE) algorithm and subclass mapping algorithm using five external independent immunotherapy cohorts. CONCLUSIONS: Our results suggest that the m6A modification participates in regulating the tumor microenvironment. The m6A-mediated immune model may be useful to predict the immunotherapy responses and outcomes of patients with LUAD.
BACKGROUND: As the most abundant modification in mRNA, the N6-methyladenosine (m6A) RNA modification is involved in the occurrence and development of various tumors. However, the underlying functions of this alteration in the immune microenvironment of lung adenocarcinoma (LUAD) remain unknown. METHODS: We identified m6A-mediated immune genes by performing a correlation analysis. Next, a m6A-mediated immune model was constructed using multiple machine learning algorithms, including univariate, least absolute shrinkage and selection operator, and multivariate Cox regression analyses. The potential of this model to predict the immune landscapes, drug sensitivities, and immunotherapy responses of different LUAD risk groups was studied. RESULTS: A m6A-mediated immune model containing 13 m6A-mediated immune genes was established and found to be an independent predictor of survival time. The prognosis of low-risk patients was significantly better than that of high-risk patients. These two risk groups displayed different immune environments, genomic backgrounds, chemotherapy responses and immunotherapy response tendencies. The low- and high-risk groups strongly corresponded to the immune-hot and immune-cold phenotypes, respectively. The low-risk group was more enriched in immune-related biological processes, and the high-risk group was more enriched in proliferation-related biological processes. Furthermore, low-risk patients responded better to immunotherapy based on the results obtained from the tumor immune dysfunction and exclusion (TIDE) algorithm and subclass mapping algorithm using five external independent immunotherapy cohorts. CONCLUSIONS: Our results suggest that the m6A modification participates in regulating the tumor microenvironment. The m6A-mediated immune model may be useful to predict the immunotherapy responses and outcomes of patients with LUAD.
Authors: Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-06-02 Impact factor: 508.702
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: M B Schabath; E A Welsh; W J Fulp; L Chen; J K Teer; Z J Thompson; B E Engel; M Xie; A E Berglund; B C Creelan; S J Antonia; J E Gray; S A Eschrich; D-T Chen; W D Cress; E B Haura; A A Beg Journal: Oncogene Date: 2015-10-19 Impact factor: 9.867
Authors: Nian Liu; Katherine I Zhou; Marc Parisien; Qing Dai; Luda Diatchenko; Tao Pan Journal: Nucleic Acids Res Date: 2017-06-02 Impact factor: 16.971
Authors: Dali Han; Jun Liu; Chuanyuan Chen; Lihui Dong; Yi Liu; Renbao Chang; Xiaona Huang; Yuanyuan Liu; Jianying Wang; Urszula Dougherty; Marc B Bissonnette; Bin Shen; Ralph R Weichselbaum; Meng Michelle Xu; Chuan He Journal: Nature Date: 2019-02-06 Impact factor: 49.962